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programs based on physical exercise might prove 
particularly beneficial. However, their use in clin‑
ical practice remains limited because of the time 
and resources needed to achieve a satisfactory 
outcome. New nonpharmacologic home ‑based 
treatment options may thus be of particular in‑
terest in this regard. Among these options, re‑
spiratory training aimed at slowing the breath‑
ing rate, was proposed some years ago. A device 
for slow breathing training (SBT) was developed 
(RESPeRATE) in order to facilitate the patient 
in the potentially difficult task of maintaining 
INTRODUCTION Chronic heart failure (CHF) has 
become one of the most widespread diseases and 
a principal cause of morbidity and mortality, due 
to the high prevalence of its main causes in ag‑
ing societies, namely, hypertension and coronary 
heart disease.1,2 Despite unquestionable progress 
in pharmacologic and device ‑based treatment, 
the mortality of CHF patients has only slight‑
ly improved in recent years,3,4 and frequent hos‑
pitalizations4 and poor quality of life5 of these 
patients remain major health care issues. Espe‑
cially in this latter aspect, cardiac rehabilitation 
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ABSTRACT
INTRODUCTION Slow breathing training (SBT) has been proposed as a new nonpharmacologic treatment 
in patients with chronic heart failure (CHF).
OBJECTIVES The aim of this study was to assess the effects of SBT on exercise capacity, hemodynamic 
parameters, and sleep respiratory patterns in a relatively large sample of CHF patients.
PATIENTS AND METHODS A crossover open study was conducted. Patients completed, in a random order, 
10- to 12 -week SBT, with 2 15 -minute sessions of device -guided SBT each day, reaching 6 breaths/
min, and a 10- to 12 -week follow -up under standard care. Clinical data collection, polysomnography, 
echocardiography, 6 -minute walk test (6MWT), and laboratory tests were performed.
RESULTS A total of 96 patients (74 men, 22 women) in New York Heart Association classes I–III, with 
an average age of 65 years and an ejection fraction (EF) of 31%, completed the study. Home -based SBT 
was safe. After training, EF and 6MWT distance improved (EF: 31.3% ±7.3% vs 32.3% ±7.7%; P = 0.030; 
6MWT: 449.9 ±122.7 m vs 468.3 ±121.9 m; P <0.001), and the apnea–hypopnea index decreased 
(5.6 [interquartile range (IQR), 2.1; 12.8] vs. 5.4 [IQR, 2.0; 10.8]; P = 0.043).
CONCLUSIONS SBT improved physical capacity and systolic heart function; it also diminished sleep 
disturbances. The results support the benefits of SBT as a novel component of cardiorespiratory reha-
bilitation programs in patients with CHF.
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PATIENTS AND METHODS Study design The 
study, performed in 2 cardiology departments 
(Kraków, Poland and Milan, Italy), employed 
a crossover open trial design where patients, 
in a random order, underwent a 10‑ to 12 ‑week 
SBT with the RESPeRATE device (InterCure Ltd., 
Lod, Israel) and a 10‑ to 12 ‑week follow ‑up un‑
der standard care. Participants were identified 
by local investigators in the period between 2012 
and 2015, and were consecutively assigned to in‑
tervention sequence starting with either SBT or 
standard care according to a previously prepared 
simple randomization list. In all patients, home 
sleep study, echocardiography, 6‑minute walk test 
(6MWT), and laboratory tests were performed 
at baseline and after each study phase (FIGURE 1). 
Optimized pharmacologic treatment was main‑
tained throughout the study. The study was per‑
formed in accordance with the 1975 Declaration 
of Helsinki for Human Research and approved 
by the Bioethical Committee of the participat‑
ing institutions: Jagiellonian University Bioeth‑
ical Committee and the Ethics Committee of Is‑
tituto Auxologico Italiano. Patients were includ‑
ed only if they gave their written informed con‑
sent. The study has been registered in the Polish 
National Science Centre (number 2011/03/B/
NZ5/00 533).
Study population Adult patients with CHF ful‑
filling the following conditions were enrolled for 
this study: NYHA classes I–III; left ventricular 
EF (LVEF) lower than 40% in echocardiograph‑
ic study; stable clinical conditions with no car‑
diovascular interventions over the previous 3 
months; receiving stable pharmacologic treat‑
ment over the previous 4 weeks; sinus rhythm 
in 24 ‑hour Holter monitoring; and ability to per‑
form breathing exercises after supervised train‑
ing. Patients after heart transplantation, patients 
who had received traditional cardiac rehabilita‑
tion within the previous 3 months, and patients 
presenting with serious chronic obstructive pul‑
monary disease, ventricular arrhythmias (tachy‑
cardia, fibrillation), or conduction abnormalities 
(second‑ and third ‑degree atrioventricular block) 
were excluded.
Slow breathing training (the RESPeRATE device) In 
the present study, patients were asked to under‑
go 2 separate 15 ‑minute sessions of device ‑guided 
SBT with the RESPeRATE device throughout 
the 10‑ to 12 ‑week period of SBT. The principles 
a constant number of breaths. This device guides 
the breathing exercise through visual and acous‑
tic feedback, and its application has been recog‑
nized by the American Heart Association as a po‑
tentially useful nonpharmacologic approach for 
lowering blood pressure.6
The use of SBT has also been shown to be 
a feasible treatment option in the framework of 
the home ‑based rehabilitation of patients with 
CHF.7 Our previously published data indicated 
that it is safe and does not significantly affect 
blood pressure values or the prevalence of ortho‑
static hypotension in these patients.8 Moreover, 
preliminary data have demonstrated the useful‑
ness of home ‑based rehabilitation in terms of im‑
proving both subjective (New York Heart Associ‑
ation [NYHA] class, breathlessness) and objective 
(exercise capacity, pulmonary function, and ven‑
tricular EF) parameters.9‑11 It was hypothesized 
that the favorable effects of SBT may be mediat‑
ed by improved baroreflex sensitivity and respi‑
ratory mechanics.9,10
Respiratory abnormalities, from shallow 
breathing to Cheyne ‑Stokes periodicity, are 
very frequent in advanced CHF and their pres‑
ence suggests a poor prognosis.12 In particular, 
sleep ‑disordered breathing, mainly character‑
ized by the presence of central apneas, is found 
in up to 76% of patients with systolic and dia‑
stolic heart failure13 and, apparently, remains in 
a dose ‑dependent relationship with heart failure 
severity.14 Intervention with positive airway pres‑
sure devices was shown to reduce the number of 
central apneas in CHF patients15 and may improve 
some clinical parameters.16 However, data from 
a recent trial suggest that adaptive servoventila‑
tion treatment is associated with higher mortali‑
ty in CHF patients.17
Alternative therapeutic options to correct 
sleep ‑disordered breathing in CHF thus remain 
to be evaluated. In this context, no information 
is available on whether a training based on slow 
breathing during the day may improve abnormal 
patterns of respiration at night.
In summary, previous data indicate that SBT 
may be a simple and clinically useful adjunct to 
cardiac rehabilitation in CHF patients but stron‑
ger evidence is needed to support its clinical use. 
Therefore, we performed this study to assess 
the effects of SBT on clinical variables, including 
exercise capacity, hemodynamic parameters, and 
respiratory patterns during sleep in a relatively 
large sample of patients with CHF.
FIGURE 1 Study 
design; group I, started 
with slow breathing 
training (SBT); group II, 
started with standard 
care
baseline
baseline
SBT
control
10–12 weeks 10–12 weeks
group I
group II
1st evaluation
1st evaluation
final evaluation
final evaluation
control
SBT
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Six ‑minute walk test The 6MWT was performed 
in patients after a 10 ‑minute resting period in 
a sitting position. Patients were asked to march 
at their own pace, on a flat and level surface in 
an empty corridor. They were informed about 
the progress of the test on regular basis; at the 
end of the 6 ‑minute period, the total distance 
walked was measured. At  baseline and after 
the test, blood pressure and oxygen saturation 
were also measured.21
Statistical analysis Considering the paucity of 
similar studies in the literature, the sample size 
was determined based on SBP effects on EF ob‑
served in the previous data from our group9: as‑
suming a sample standard deviation of 8% and 
a correlation coefficient of 0.6 between EF be‑
fore and after the intervention, 103 patients were 
needed to identify a 2% difference in EF with 
a power of 80%.
All data were analyzed using the Statistica PL 
v.12.0 software (StatSoft, Tulsa, Oklahoma, Unit‑
ed States). Categorical variables were reported 
as percentages, while continuous variables—as 
means and standard deviations or median and 
interquartile ranges when data distribution dif‑
fered from the normal. The χ2 test was applied 
for all categorical variables. For continuous vari‑
ables, the analysis of variance for repeated mea‑
sures was applied. If the assumptions were not 
met, a multidimensional approach or the Fried‑
man test was used. For statistically significant re‑
sults, detailed comparisons using the appropriate 
post hoc testing (Tukey tests) were conducted. To 
assess changes in only 2 measurements, the t test 
for paired samples or the Wilcoxon matched pairs 
test was used. The results for which the P value 
was lower than the assumed level of significance 
α = 0.05 (P <0.05) were considered significant.
RESULTS We included 110 patients (age, 23–87 
years; 86 men and 24 women), of whom 14 did 
not complete the study for the following reasons: 
2 sudden cardiac deaths; cardiac resynchroniza‑
tion therapy device implantation; 2 hospitaliza‑
tions (myocardial infarction and limb fracture); 
alcohol addiction; overnight working; 4 changed 
the place of residence; 3 withdrew from further 
participation in the study (health reasons were 
excluded). Consequently, the trial ended after 96 
subjects completed the study (74 in Kraków, 22 in 
Milan; age, 23–86 years; 74 men and 22 women).
Owing to a specific study design (crossover 
open trial), in order to verify the probability of 
a significant carryover effect, we preliminarily as‑
sessed the interactions between the intervention 
sequence (SBT first vs control first) and the ob‑
served effects, and found no significant interac‑
tions (P value always >0.4). Thus, the results could 
be safely pooled together.
The clinical characteristics of the patients are 
shown in TABLE 1, separately for male and female 
participants. Male participants had slightly high‑
er body mass index and more frequent ischemic 
of functioning of this device were described previ‑
ously.18 Briefly, after a “learning” phase of the pa‑
tient’s respiratory pattern, the device guides 
the patient’s breathing by means of a musical 
pattern and gradually reduces breathing frequen‑
cy to 6 breaths/min, while maintaining a desired 
inspiration/expiration time ratio.8
Echocardiography Echocardiography was per‑
formed using Vivid 7 Pro (General Electric, Fair‑
field, Connecticut, United States), with a 2.5 ‑MHz 
probe by a single experienced operator who was 
blinded to the patients’ allocation to experimen‑
tal groups. One ‑dimensional, two ‑dimensional, 
pulse, and continuous Doppler, and pulsed ‑wave 
tissue Doppler imaging methods incorporating 
the measurement of individual phases of mitral 
annulus velocity were used. Each point of the pro‑
tocol was recorded for at least 3 cardiac cycles dur‑
ing patients’ steady breathing. The data were re‑
corded, stored, and analyzed using the Echo ‑Pack 
system (General Electric). EF was calculated using 
the Simpson’s formula. In the presence of tricus‑
pid regurgitation, the tricuspid regurgitation pres‑
sure gradient and the value of right atrial pressure 
estimated on the basis of the width and the re‑
spiratory subsidence of the vena cava were used 
to assess the systolic pressure in the right ventri‑
cle. Right ventricular systolic pressure was calcu‑
lated by adding the values of tricuspid regurgita‑
tion pressure gradient and right atrial pressure.19
Home sleep study Home sleep study was per‑
formed with Embletta Gold, an ambulatory over‑
night cardiorespiratory device (Embla, Broom‑
field, Colorado, United States), which recorded 
nasal/oral airflow (via a pressure cannula), chest 
and abdominal wall movements (via inductive 
belts), oxygen saturation (via a finger probe pulse‑
‑oximetry) and heart rate (via a CM5 device). 
A breathing event was defined as abnormal if: 
1) a complete cessation of airflow lasting more 
than 10 seconds was present (apnea); or 2) a re‑
duction in respiratory airflow greater than 50% 
and lasting more than 10 seconds and associat‑
ed with a desaturation of 4% or higher (hypop‑
nea) occurred. Obstructive apneas were defined 
by a reduction of respiratory airflow of over 50% 
for a minimum of 10 seconds, associated with par‑
adoxical thoracic and abdominal motion and a de‑
saturation of 4% or higher. Central apneas were 
defined by the absence/reduction of respirato‑
ry airflow for 10 seconds with an absence of tho‑
racic and abdominal excursions and a desatura‑
tion of 4% or higher. The apnea–hypopnea index 
(AHI) was defined as the average number of ap‑
neas and hypopneas per hour of sleep. A sleep‑
‑related breathing disorder was diagnosed when 
the AHI was 5 or higher. Cheyne –Stokes respira‑
tion was characterized by the lack of air flow and 
respiratory effort followed by hyperventilation in 
a crescendo ‑decrescendo pattern.20
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During the study, no patient reported safety 
issues related to study procedures and no adverse 
events attributable to the intervention occurred.
DISCUSSION Our study attempted to assess 
a number of clinically relevant parameters in a rel‑
atively large sample of patients with CHF before 
and after SBT. We indeed confirmed previous 
findings showing that SBT may improve cardiac 
function and functional performance. Further‑
more, our study investigated for the first time 
the effects of SBT on sleep ‑disordered breathing 
in these patients.
Previous studies have suggested that slow 
breathing or SBT may be a useful adjunct to 
standard CHF treatment. Acute effects of slow 
breathing in patients with heart failure were as‑
sessed by Bernardi et al,10 who reported an in‑
crease in blood oxygenation levels and improved 
exercise performance in participants who under‑
went 1 ‑month training. Improvement in blood ox‑
ygenation seems to be related to an improved re‑
spiratory mechanics with increased alveolar ven‑
tilation10 as shown also by a study in subjects ex‑
posed to hypoxia.22
The information on the beneficial effects of SBT 
was further extended by a pilot study by Parati 
et al,9 in which SBT was performed with the same 
device as was used in the present study. These ef‑
fects included reductions in both the NYHA class 
and sPAP, as well as improvement in EF, ventila‑
tory parameters, and quality of life.
Furthermore, Ekman et al11 found an improve‑
ment in NYHA class and breathlessness after 1 
month of SBT with the RESPeRATE device.
etiology and sleep apneas, both central and ob‑
structive. Of 96 patients, 20 had mild to mod‑
erate obstructive sleep apnea and 6 had mild to 
moderate central sleep apnea. On the other hand, 
there were no significant differences in baseline 
characteristics according to the intervention se‑
quence (initial SBT versus initial control period).
The main clinical variables before and after 
the period of SBT are presented in TABLE 2. We 
observed a significant reduction in global AHI 
(from 5.6 [2.1–12.8] to 5.35 [2.0–10.8], P = 0.043), 
and a trend for a reduction in central apneas in 
the whole population (P = 0.16); central apne‑
as were significantly reduced in men (P = 0.039) 
(even if the median values were close to 0 due to 
highly skewed distribution) but not in women 
(P = 0.21). No significant changes in obstructive 
apneas were observed (TABLE 2).
There was a significant improvement in LVEF 
after SBT (31.3% ±7.3% vs 32.3% ±7.7%; P = 
0.030), accompanied by a  reduction in end‑
‑diastolic diameter of the left ventricle and a trend 
for a reduction in the E/A ratio, while no change 
was observed in systolic pulmonary artery pres‑
sure (sPAP). The increase in LVEF was more ev‑
ident in women (from 32.8% to 35.3%) than in 
men (from 30.8% to 31.4%; P for interaction = 
0.07), and in patients with NYHA class I (from 
34.4% to 37.6%) compared with those with class‑
es II (from 31.1% to 32.5%) and III (from 30.2% to 
28.9%; P for interaction = 0.018), while no effect 
of CHF etiology was observed (TABLE 2).
The 6MWT distance increased after SBT (449.9 
±122.7 m vs 468.3 ±121.9 m; P <0.001; TABLE 2), 
regardless of the intervention sequence (FIGURE 2).
TABLE 1 Baseline characteristics of study participants
Parameter All participants 
(n = 96)
Male participants 
(n = 74)
Female participants 
(n = 22)
P value
age, y 64.5 (57.0–71.5) 64.5 (57.0–72.0) 64.5 (56.0–69.0) NS
BMI, kg/m2 26.4 (24.4–29.1) 26.9 (24.4–30.1) 25.0 (21.8–27.1) 0.036
NYHA class I–III, n 11/65/20 7/49/16 4/14/4 NS
EF, % 31.0 (25.0–37.0) 30.0 (25.0–36.0) 32.5 (27.0–38.0) NS
sPAP, mmHg 35.0 (30.0–44.5) 35.0 (30.0–45.0) 32.5 (30.0–44.0) NS
office SBP, mmHg 131.0 (118.0–140.0) 131.5 (118.5–140.3) 126.0 (112.0–138.0) NS
office DBP, mmHg 80.8 (72.0–87.0) 81.0 (74.3–87.3) 79.0 (68.5–85.0) NS
6MWT distance, m 440.0 (360.0–521.0) 459.0 (380.0–525.0) 410.0 (324.0–462.0) NS
AHI, 1/h 6.6 (2.6–14.2) 10.0 (3.0–16.0) 4.9 (1.0–6.6) 0.001
central AHI 0.1 (0.0–0.7) 0.1 (0.0–1.0) 0.0 (0.0–0.1) 0.048
obstructive AHI 2.0 (0.4–4.3) 2.3 (0.5–6.0) 1.0 (0.3–2.3) 0.038
ischemic 
etiology, n (%)
67 (69.1) 56 (75.7) 11 (50) 0.021
β -blockers, n (%) 88 (91.7) 67 (90.5) 21 (95.5) NS
ACEI/ARB, n (%) 69 (71.9) 54 (73.0) 15 (68.2) NS
diuretics, n (%) 69 (71.9) 52 (70.3) 17 (77.3) NS
Data are presented as median (interquartile range) unless stated otherwise.
Abbreviations: 6MWT, 6 -minute walk test; ACEI, angiotensin -converting enzyme inhibitor; AHI, apnea–hypopnea index; 
ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; EF, ejection fraction; NYHA, 
New York Heart Association; NS, nonsignificant; SBP, systolic blood pressure; sPAP, systolic pulmonary artery pressure
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ble effect on respiratory muscles.23 Our results 
are consistent with the results of the study by 
Parati et al,9 although in the current study the in‑
crease in LVEF was less pronounced (Parati et al9 
reported an increase in LVEF from 32% ±6% to 
In our study, we demonstrated that SBT led 
to a significant increase in LVEF in patients with 
CHF. This improvement might be the result of 
increasing the sensitivity of baroreceptor reflex 
and respiratory mechanics itself,9 with a possi‑
TABLE 2 Key clinical variables before and after slow breathing training
Parameter All participants (n = 96) Male participants (n = 74) Female participants (n = 22)
before SBT after SBT P value before SBT after SBT P value before SBT after SBT P value
6MWT, m 449.9 
±122.7
468.3 ±121.9 <0.001 461 
(389–529)
480 
(402–574)
<0.001 420 ±134 427 ±135 NS
sleep parameters
AHI, 1/h 5.6 (2.1–12.8) 5.4 (2.0–10.8) 0.043 7.2 
(2.6–15.6)
6.5 (2.5–12.4) 0.013 4.0 ±4.3 4.8 ±4.8 NS
AI central 0.0 (0.0–0.7) 0.0 (0.0–0.6) NS 0.1 (0.0–1.1) 0.1 (0.0–0.7) 0.039 0.0 
(0.0–0.1)
0.0 
(0.0–0.4)
NS
AI obstructive 1.6 (0.4–4.1) 1.4 (0.5–4.6) NS 1.8 (0.5–5.3) 1.6 (0.4–5.2) NS 1.2 ±1.6 1.9 ±2.1 NS
echocardiography 
LVEDd, mm 61 (56–65) 60 (56–66) 0.023 62 (58–66) 61 (57–67) 0.041 57 ±7 57 ±7 NS
LVESd, mm 49 (43–54) 49 (43–55) NS 50 (44–54) 50 (44–56) NS 45 (39–52) 43 (40–47) NS
E/A ratio 0.80 
(0.65–1.44)
0.77 
(0.67–1.20)
0.061 0.79 
(6.4–1.45)
0.77 
(0.63–1.22)
NS 1.08 ±0.56 0.95 ±0.40 NS
sPAP, mmHg 35 (29–43) 35 (28–40) NS 35 (27–43) 35 (27–40) NS 33 (30–38) 31 (30–43) NS
LVEF,% 31 ±7 32 ±8 0.030 31 ±7 31 ±7 NS 33 (26–38) 35 (32–40) 0.005
Data are presented as mean ± SD or median (interquartile range) as appropriate.
Abbreviations: AI, apnea index; E/A, early-to-late ventricular filling velocity ratio; LVEDd, left ventricular end -diastolic diameter; LVEF, left ventricular 
ejection fraction; LVESd, left ventricular end -systolic diameter; SBT, slow breathing training; others, see TABLE 1
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FIGURE 2 Changes in 
the 6 -minute walk test 
(6MWT) distance 
between study phases 
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breathing training; group 
II, started with standard 
care; data presented as 
mean ± standard error 
a significant differences
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having no central apneas). This was probably due 
to the fact that our intervention was not specifi‑
cally aimed at reducing the burden of sleep apne‑
as but rather at assessing clinical effects of SBT in 
a representative group of CHF patients followed 
in rehabilitation programs. Therefore, study par‑
ticipants had on average relatively mild CHF with 
good functional performance (79% of patients 
were classified as NYHA class II or lower), were in 
stable conditions, and had only modestly elevat‑
ed body mass index (median, 26.4 kg/m2). There‑
fore, since the prevalence of both central and ob‑
structive sleep apneas was low, the conceivable 
benefits of SBT were limited. Also in this case 
we observed a difference between sexes; howev‑
er, contrary to what was observed for the chang‑
es in LVEF, an improvement in central apneas was 
only evident in male participants, possibly due to 
a higher central apnea index at baseline. 
The finding of the higher rate of central apne‑
as in men is in line with an increase in the prev‑
alence of central apneas in patients with CHF26 
and in healthy subjects exposed to high altitude 
where central apneas are common.27 As a conse‑
quence of our findings, we believe that a study in‑
cluding specifically a sample of patients with CHF 
and sleep ‑disordered breathing would be justified. 
Considering that an optimization of heart failure 
treatment may alleviate central sleep apnea,28,29 
and in the wake of recent controversies regard‑
ing whether or not central sleep apnea should 
be specifically targeted in heart failure patients, 
a new therapeutic option targeting the patho‑
physiological basis of central apneas might be of 
particular interest.
In our previous analyses, we did not show sig‑
nificant changes in blood pressure values after 
SBT.8 The RESPeRATE device has been success‑
fully used to lower blood pressure in patients 
with hypertension. The lack of significant chang‑
es in blood pressure values in the studied group 
could be attributed to low prevalence of elevat‑
ed blood pressure.
Our data showed an improvement in exercise 
capacity in the 6MWT after SBT. According to 
current guidelines, the 6MWT is easy to admin‑
ister and provides strong indications for measur‑
ing the response to medical intervention in pa‑
tients with heart failure.21 In ambulatory patients 
with systolic heart failure, 6MWT provides prog‑
nostic utility comparable to that of cardiopulmo‑
nary exercise tests, which is the gold standard for 
the assessment of exercise capacity in this group 
of patients.30
The  improvement in physical capacity on 
the basis of the bicycle cardiopulmonary exer‑
cise test in patients with heart failure treated 
with monthly respiratory training was reported 
by Bernardi et al.10 After 1 month of respirato‑
ry muscle training, Mancini et al31 found an im‑
provement in exercise capacity based on the re‑
sults of the 6MWT. Thus far, only the pilot study 
by Parati et al, which had similar duration and 
the same protocol as our study with the use of 
39% ±9%). Similarly, in our population, we did 
not show a positive effect of SBT on the reduc‑
tion of sPAP. These results differ from the results 
of the pilot study, where sPAP decreased from 49 
±17 mmHg to 38 ±9 mmHg after 10 weeks of SBT.
These discrepancies could be explained by 
the fact that the pilot study included patients 
with significantly higher baseline sPAP values: 
the baseline condition of more severely impaired 
pulmonary hemodynamics could have amplified 
a potentially favorable effect of slow breathing, 
less evident in the current study.9 On the other 
hand, the controlled design of our study might 
also have reduced the foreseeable bias of a small 
uncontrolled study. Indeed, our data are in agree‑
ment with the results of a study by Fox et al24 in 
patients with pulmonary hypertension, in whom 
6 weeks of exercise training led to a significant im‑
provement in the 6MWT distance despite non‑
significant changes in echocardiography param‑
eters such as stroke volume and sPAP. Interest‑
ingly, the benefits in terms of LVEF improvement 
were mostly evident in female participants and in 
those with clinically milder CHF. Sex differences 
in response to exercise training in patients with 
CHF were previously reported by Pina et al,25 who 
found greater benefits (measured by peak oxygen 
consumption and 6MWT) in women than in men 
with CHF. Although in our sample there was no 
significant difference between men and women in 
terms of a change in the 6MWT distance, the find‑
ing of improved LV function after SBT restrict‑
ed to female sex may further support the useful‑
ness of rehabilitation techniques in this group.
Sleep ‑disordered breathing is commonly seen 
in systolic and diastolic heart failure. Sleep ap‑
nea comprises several forms of sleep ‑disordered 
breathing. Although the pathophysiology of cen‑
trally driven apneas differs considerably com‑
pared with that of obstructive sleep apnea, they 
share multiple consequences. The differential di‑
agnosis of the 2 forms of sleep apnea is based on 
polysomnographic studies where the presence or 
absence of respiratory movements distinguishes 
obstructive from central episodes. Apparently, 
there is a dose ‑dependent relationship between 
sleep disorders and the severity of heart failure, 
with a gradual increase in central sleep apnea 
occurrence along with the progression of cardi‑
ac failure.14
In our study, the AHI score equaled 6.6 (in‑
terquartile range, 2.6–14.2) at baseline. Never‑
theless, the use of SBT resulted in an overall im‑
provement in breathing stability during sleep as 
the AHI modestly decreased after active treat‑
ment (TABLE 2).
We observed a trend towards a reduced num‑
ber of central apneas and hypopneas (P = 0.16), 
whereas no change was observed in obstructive 
episodes. Arguably, the absolute benefit in terms 
of improvement in sleep ‑disordered breathing was 
modest (the median central apnea index values 
equal to 0 derived from a highly skewed distribu‑
tion of this variable with numerous participants 
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the RESPeRATE device, showed an improvement 
in exercise capacity based on the bicycle cardio‑
pulmonary test.9 The meta ‑analysis by Monte‑
mezzo et al32 of all studies on the use of respira‑
tory rehabilitation in patients with heart failure 
confirms its beneficial effects on physical per‑
formance and usefulness in clinical practice, al‑
though it should be emphasized that the number 
of these studies is low.
Our study has several strengths. First, the re‑
spiratory profile after SBT with RESPeRATE had 
never been tested previously; second, the sam‑
ple size was larger than in most previous stud‑
ies9,11; third, the controlled design and the use 
of a device designed for SBT (and approved by 
the Food & Drug Administration for blood pres‑
sure lowering) followed a standardized exercise 
protocol. Furthermore, this device implements 
a series of features that make the exercise eas‑
ier for the patient, including the individualized 
acoustic guidance of breathing frequency, which 
results in its gradual reduction, and visual feed‑
back on the exercise performance. This is impor‑
tant as self ‑maintenance of a constant number of 
breaths by the patient is a difficult task, and rig‑
id breathing pacing could have a negative effect 
on exercise performance.
There are also a few limitations. First, the ma‑
jority of enrolled patients were in NYHA class II, 
thus the information on the tolerability and effi‑
cacy in more severe CHF is limited. Second, since 
for practical reasons we implemented a crossover 
rather than a parallel ‑group design, there might 
have been a carryover effect; however, the lack 
of interaction of the intervention sequence with 
the observed changes suggests that such an ef‑
fect was not relevant. Third, a strict supervision 
of exercise quality in patients’ homes was not 
performed, and the observed effect might have 
been diluted by participants who were not com‑
pliant with the training. Fourth, we did not as‑
sess breathing pattern during daytime and there‑
fore have no data on the presence of central ap‑
neas in the awake period.33 Finally, we could not 
exclude the possible influence of comorbidities 
(eg, diabetes, hypertension) or drugs on the re‑
sults, although pharmacotherapy was kept sta‑
ble during the study.
In conclusion, in patients with stable chronic 
systolic heart failure, SBT improved physical ca‑
pacity and systolic left ventricular function, with 
a tendency to attenuate sleep disturbances, main‑
ly central apnea. The latter results support the hy‑
pothesis that central sleep apnea may represent 
a consequence of heart failure or an adaptation 
mechanism to the complex neurohormonal ab‑
normalities observed in these patients. We be‑
lieve that device ‑guided SBT may be successfully 
implemented as a home ‑based rehabilitation tool 
in patients with CHF, leading to improvements 
in their clinical status and breathing patterns.
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